Director dealings: Bioventix chairman raises stake
13th Apr 2026 13:56
(Sharecast News) - Bioventix revealed on Monday that chairman Ian Nicholson had acquired 1,000 ordinary shares in the AIM-listed biotechnology firm.
Read moreDirector dealings: Bioventix chairman raises stake
13th Apr 2026 13:56
(Sharecast News) - Bioventix revealed on Monday that chairman Ian Nicholson had acquired 1,000 ordinary shares in the AIM-listed biotechnology firm.
Read moreChina weakness sees profits fall for Bioventix
27th Oct 2025 10:24
(Sharecast News) - Bioventix reported lower annual profits on Monday, as weakness in its core markets, particularly China, offset gains from growing demand for its neurological diagnostic antibodies.
Read moreRevenue rises, profit falls for Bioventix
31st Mar 2025 13:56
(Sharecast News) - Bioventix reported a marginal rise in revenue for the six months ended 31 December on Monday, with profit before tax dipping slightly due to higher research and development expenditure.
Read moreDirector dealings: Bioventix CFO raises stake
31st Oct 2024 15:15
(Sharecast News) - Bioventix revealed on Thursday that chief financial officer Bruce Hiscock had acquired 333 ordinary shares in the London-listed antibodies development and supply company.
Read moreBioVentix reports year of growth, warns of geopolitical risks
28th Oct 2024 09:32
(Sharecast News) - BioVentix, a UK-based developer of high-affinity monoclonal antibodies for clinical diagnostics, reported a 6% improvement in full-year revenue on Monday, to £13.6m, up from £12.82m in the prior year.
Read moreBioVentix revenue, earnings rise in first half
25th Mar 2024 12:17
(Sharecast News) - Monoclonal antibody specialist BioVentix reported a 13% rise in first-half revenue on Monday, to £6.7m, compared to £5.9m in the prior year.
Read moreSunday share tips: Octopus Renewables Infrastructure Trust, Bioventix
19th Nov 2023 21:24
(Sharecast News) - The Financial Mail on Sunday's Midas column tipped the Octopus Renewables Infrastructure Trust to readers, pointing out its 7% dividend yield and the current valuation of its shares.
Read moreBioVentix revenue, profits improve in full-year results
24th Oct 2022 11:55
(Sharecast News) - Diagnostic monoclonal antibody specialist BioVentix reported a 7% improvement in revenue in its full-year results on Monday, to £11.72m.
Read moreBioventix hikes interim dividend after revenue falls
28th Mar 2022 11:48
(Sharecast News) - Monoclonal antibody developer and supplier Bioventix reported an 8% fall in revenue in its first half on Monday, to £4.7m.
Read moreBioventix revenue rises in tougher first half
29th Mar 2021 08:58
(Sharecast News) - Diagnostic antibody developer Bioventix reported a 1.3% improvement in revenue in its first half on Monday, to £5.2m.
Read moreBioventix appoints Bruce Hiscox as chief financial officer
1st Jul 2020 09:40
(Sharecast News) - Antibodies developer Bioventix named Bruce Hiscock would join the group its new chief financial officer on Wednesday.
Read moreBioventix full-year revenue and profits improve
21st Oct 2019 11:33
(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.
Read moreVitamin D antibodies drive first-half growth at Bioventix
29th Mar 2019 08:31
(Sharecast News) - Monoclonal antibodies developer and supplier Bioventix reported a 24% improvement in its normalised revenue in its half-year report on Friday, to £4.4m.
Read moreBioventix posts healthy profits, ups dividend; warns of plateauing vit-D sales
8th Oct 2018 12:09
(Sharecast News) - Aim's Bioventix announced Monday it would pay a special dividend after a strong year of revenue and profit growth - but also sounded a warning over one of its key revenue streams.
Read more